Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: a multicentre, open-label, parallel-group, phase II-III, randomised superiority study (CAIRO6)

Catharina HospitalMichelangelolaan 25623 EJ, EindhovenThe Netherlands0 sites358 target enrollmentTBD

ConditionsColorectal cancer with isolated peritoneal metastases

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Colorectal cancer with isolated peritoneal metastases
Sponsor: Catharina HospitalMichelangelolaan 25623 EJ, EindhovenThe Netherlands
Enrollment: 358
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Rovers KP, Simkens GA, Punt CJ, et al. Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? A critical systematic review. Crit Rec Oncol Hematol. 2017;114:53-62.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Catharina HospitalMichelangelolaan 25623 EJ, EindhovenThe Netherlands

Eligibility Criteria

Inclusion Criteria

•Eligible patients are adults who have:
•a World Health Organisation (WHO) performance status of ≤1;

Exclusion Criteria

•Patients are excluded in case of any comorbidity or condition that prevents safe administration of the planned perioperative systemic therapy, determined by the treating medical oncologist, e.g.:

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 1

Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer

EUCTR2016-001865-99-NLCatharina Ziekenhuis358

Recruiting

Phase 3

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone: a multicentre, open-label, parallel-group, phase II-III, randomised superiority study (CAIRO6).Peritoneal metastases of colorectal cancerColon cancer with metastases in the peritoneum100346521001799110017998

NL-OMON55637Catharina-ziekenhuis298

Active, not recruiting

Phase 2

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal MetastasesColorectal NeoplasmColorectal CancerColorectal Neoplasms MalignantColorectal CarcinomaColorectal AdenocarcinomaPeritoneal NeoplasmsPeritoneal CarcinomatosisPeritoneal CancerPeritoneal MetastasesPeritoneal Neoplasm Malignant Secondary CarcinomatosisPeritoneal Neoplasm Malignant Secondary

NCT02758951Koen Rovers358

Recruiting

Not Applicable

Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (OrganoHIPEC)Peritoneal Metastases From Colorectal Cancer

NCT06057298Fondazione IRCCS Istituto Nazionale dei Tumori, Milano24

Active, not recruiting

Phase 1

Surgery and abdominal chemotherapy for patient with peritoneal metastasized stomach cancerPeritoneal carcinomatosis of gastric originMedDRA version: 20.0 Level: LLT Classification code 10017767 Term: Gastric cancer stage IV with metastases System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2016-002595-27-NLniversity Medical Center Utrecht20